Sacituzumab govitecan
Trodelvy (sacituzumab govitecan) is an antibody pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. The pharmaceutical is active against tumor-associated calcium signal transducer 2.
| Trade Name | Trodelvy |
|---|---|
| Common Name | Sacituzumab govitecan |
| Indication | triple negative breast neoplasms |
| Drug Class | Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives) |
